Clinical Trial Update: Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers [Phase 1]

View source ↗

Summary

Phase 1 clinical trial assessing mesothelin/GPC3/GUCY2C-targeted CAR-T cells for pancreatic cancer and other solid tumors; recruitment is ongoing in China.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Mesothelin/GPC3/GUCY2C-CAR-T cells (CAR-T cell therapy targeting mesothelin, GPC3, and GUCY2C)

Snippet

Sponsor: Second Affiliated Hospital of Guangzhou Medical University | Conditions: Pancreas Cancer, CAR-T Cell Therapy | Phase 1 | Status: RECRUITING